Aidigong Maternal & Child Health Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Aidigong Maternal & Child Health.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	19.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Take Care Before Jumping Onto Aidigong Maternal & Child Health Limited (HKG:286) Even Though It's 28% Cheaper

Mar 22

A Look At The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Jul 06

Aidigong Maternal & Child Health Limited (HKG:286) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Jun 14

Calculating The Intrinsic Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Mar 27

Is Aidigong Maternal & Child Health Limited (HKG:286) Trading At A 24% Discount?

Dec 21

Is Aidigong Maternal & Child Health (HKG:286) Using Debt In A Risky Way?

Oct 13

Estimating The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Sep 02

Aidigong Maternal & Child Health (HKG:286) Has A Somewhat Strained Balance Sheet

Jun 29

Aidigong Maternal & Child Health (HKG:286) Use Of Debt Could Be Considered Risky

Aug 31

Do Institutions Own Aidigong Maternal & Child Health Limited (HKG:286) Shares?

Feb 21

Is Aidigong Maternal & Child Health Limited's (HKG:286) Stock Price Struggling As A Result Of Its Mixed Financials?

Jan 17

Aidigong Maternal & Child Health's(HKG:286) Share Price Is Down 14% Over The Past Three Years.

Dec 12

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aidigong Maternal & Child Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:286 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	555	-177	N/A	N/A	N/A
9/30/2023	606	-152	N/A	N/A	N/A
6/30/2023	658	-127	216	254	N/A
3/31/2023	669	-146	147	184	N/A
12/31/2022	680	-165	77	115	N/A
9/30/2022	664	-123	72	103	N/A
6/30/2022	647	-80	66	91	N/A
3/31/2022	645	-37	73	98	N/A
12/31/2021	643	5	80	105	N/A
9/30/2021	622	-189	66	84	N/A
6/30/2021	601	-384	51	63	N/A
3/31/2021	601	-383	4	16	N/A
12/31/2020	601	-381	-43	-32	N/A
9/30/2020	653	-172	-119	-105	N/A
6/30/2020	704	37	-195	-178	N/A
3/31/2020	657	24	-106	-89	N/A
12/31/2019	611	11	-17	0	N/A
9/30/2019	492	3	5	27	N/A
6/30/2019	374	-5	28	53	N/A
3/31/2019	376	-1	21	47	N/A
12/31/2018	377	2	15	41	N/A
9/30/2018	452	2	-41	-17	N/A
6/30/2018	528	3	-96	-75	N/A
3/31/2018	501	2	-83	-62	N/A
12/31/2017	475	1	-71	-50	N/A
9/30/2017	496	8	N/A	-90	N/A
6/30/2017	517	14	N/A	-131	N/A
3/31/2017	536	28	N/A	-128	N/A
12/31/2016	555	42	N/A	-124	N/A
9/30/2016	583	51	N/A	-4	N/A
6/30/2016	610	59	N/A	116	N/A
3/31/2016	570	47	N/A	116	N/A
12/31/2015	530	34	N/A	117	N/A
6/30/2015	485	27	N/A	-56	N/A
3/31/2015	422	24	N/A	-72	N/A
12/31/2014	360	20	N/A	-89	N/A
6/30/2014	17	-10	N/A	-21	N/A
3/31/2014	13	-6	N/A	-50	N/A
12/31/2013	9	-3	N/A	-79	N/A
9/30/2013	9	1	N/A	-120	N/A
6/30/2013	8	-8	N/A	-84	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 286's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if 286's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 286's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 286's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 286's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 286's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Aidigong Maternal & Child Health Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Aidigong Maternal & Child Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Price target decreased to HK$0.60

Aidigong Maternal & Child Health Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Price target decreased to HK$0.65

Recent updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Take Care Before Jumping Onto Aidigong Maternal & Child Health Limited (HKG:286) Even Though It's 28% Cheaper

Aidigong Maternal & Child Health Limited has filed a Follow-on Equity Offering in the amount of HKD 62.09021 million.

Aidigong Maternal & Child Health Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Insider selling

Chairman & CEO recently sold HK$8.4m worth of stock

New major risk - Share price stability

Chairman & CEO recently bought HK$1.4m worth of stock

New minor risk - Shareholder dilution

Chairman of the Board & CEO recently bought HK$247k worth of stock

Aidigong Maternal & Child Health Limited Announces Board and Committee Changes

Aidigong Maternal & Child Health Limited Announces Resignation of Guo Qifei Has as Non-Executive Director

First half 2023 earnings released: HK$0.005 loss per share (vs HK$0.014 loss in 1H 2022)

First half 2023 earnings released: HK$0.005 loss per share (vs HK$0.014 loss in 1H 2022)

Aidigong Maternal & Child Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Aidigong Maternal & Child Health Limited to Report First Half, 2023 Results on Aug 31, 2023

Executive Director recently bought HK$6.3m worth of stock

A Look At The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Aidigong Maternal & Child Health Limited (HKG:286) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Full year 2022 earnings: EPS and revenues miss analyst expectations

Calculating The Intrinsic Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Now 22% undervalued after recent price drop

Aidigong Maternal & Child Health Limited Announces Director Appointments

Is Aidigong Maternal & Child Health Limited (HKG:286) Trading At A 24% Discount?

Aidigong Maternal & Child Health Limited announced that it expects to receive HKD 224.719102 million in funding from Zhuhai Deyou Bohui Enterprise Management Consulting (Limited Partnership)

Now 24% undervalued after recent price drop

Aidigong Maternal & Child Health Limited Announces Executive Changes

Price target decreased to HK$0.60

Less than half of directors are independent

Is Aidigong Maternal & Child Health (HKG:286) Using Debt In A Risky Way?

First half 2022 earnings released: HK$0.014 loss per share (vs HK$0.006 profit in 1H 2021)

Now 25% undervalued

Estimating The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

First half 2022 earnings released: HK$0.014 loss per share (vs HK$0.006 profit in 1H 2021)

Aidigong Maternal & Child Health Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Aidigong Maternal & Child Health Limited Announces Resignation of Wong Kin Man as a Non-Executive Director

Aidigong Maternal & Child Health (HKG:286) Has A Somewhat Strained Balance Sheet

Aidigong Maternal & Child Health Limited, Annual General Meeting, Jun 28, 2022

Aidigong Maternal & Child Health Limited Announces Resignation of Yang Zhibo as Non-Executive Director

Price target decreased to HK$0.65

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Chairman of the Board & CEO recently bought HK$1.2m worth of stock

First half 2021 earnings released: EPS HK$0.006 (vs HK$0.007 in 1H 2020)

Independent Non Executive Director Yang Guang Mai has left the company

Aidigong Maternal & Child Health (HKG:286) Use Of Debt Could Be Considered Risky

First half 2021 earnings released: EPS HK$0.006 (vs HK$0.007 in 1H 2020)

Aidigong Maternal & Child Health Limited has completed a Follow-on Equity Offering in the amount of HKD 117.8 million.

An unknown buyer entered into an agreement to acquire 49% stake Shenzhen Wanqi Marine Bio Tech Company Limited from Aidigong Maternal & Child Health Limited (SEHK:286) for HKD 25 million.

Full year 2020 earnings released: HK$0.10 loss per share (vs HK$0.004 profit in FY 2019)

Aidigong Maternal & Child Health Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Do Institutions Own Aidigong Maternal & Child Health Limited (HKG:286) Shares?

New 90-day high: HK$0.62

Is Aidigong Maternal & Child Health Limited's (HKG:286) Stock Price Struggling As A Result Of Its Mixed Financials?

New 90-day low: HK$0.45

Aidigong Maternal & Child Health's(HKG:286) Share Price Is Down 14% Over The Past Three Years.

New 90-day low: HK$0.50

New 90-day low: HK$0.52

New 90-day low: HK$0.56

Aidigong Maternal & Child Health Limited to Report First Half, 2020 Results on Aug 28, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies